Browse the evidence

41.9% of the US population is classified as obese.

Practitioners should be aware of the significant prevalence of obesity in the population.

There was no significant effect of the intervention on daily steps, daily activity energy expenditure, or moderate-to-vigorous physical activity compared to the control group.

Practitioners should note that the program did not significantly increase physical activity levels.

Infertility affects up to 17.5% of the global population.

Awareness of the prevalence of infertility can guide public health initiatives.

Body and fat mass and blood glucose levels are not regulated, controlled, or defended.

Practitioners should reconsider the concepts of regulation and control in metabolism when addressing obesity.

The 'Invisible Hand of Metabolism' illustrates unregulated behavior of cells affecting physiological states.

Understanding cellular behavior can help in developing strategies for obesity management.

Sugar-sweetened beverage companies have successfully marketed their products by associating them with global cultural and sporting events.

Awareness of marketing tactics can help consumers make informed choices about beverage consumption.

The BB-Health study will evaluate age-sensitive cognitive assessments and cerebral hemodynamics as outcomes.

Practitioners should monitor cognitive health and cerebral hemodynamics in interventions.

GLP-1 RAs slow both thoracic and abdominal aneurysm growth.

GLP-1 RAs may be beneficial in managing aneurysms in clinical settings.

Resmetirom is the first drug approved for MASLD, demonstrating histological efficacy in addressing both steatohepatitis and fibrosis.

Practitioners can consider resmetirom as a treatment option for MASLD.

The review discusses the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders.

Understanding the role of metabolic drugs in managing inflammatory comorbidities can enhance treatment strategies.

Metabolic drugs may be repurposed as direct anti-inflammatory agents.

Exploring the repurposing of metabolic drugs could lead to new anti-inflammatory therapies.

Treatment-limiting gastrointestinal side effects occurred in 16.7% of patients.

Clinicians should monitor for gastrointestinal side effects in patients taking semaglutide.

The translational application of browning agents in humans faces challenges.

Practitioners should be aware of the limitations when considering browning agents for treatment.

No significant associations were found between GLP-1 receptor agonists or SGLT2 inhibitors and risk of sepsis, abscess, gangrene, or other infections.

Practitioners can be reassured about the lack of infection risk associated with these medications.

The relationship among cardiovascular disease, chronic kidney disease, and metabolic diseases is recognized as 'cardiovascular-kidney-metabolic (CKM) syndrome'.

Clinicians should consider the interconnectedness of these diseases in treatment.

Specialist clinicians have historically approached cardiovascular, kidney, and metabolic disorders as separate diseases.

Clinicians may need to reconsider their treatment strategies to integrate care for CKM syndrome.

Obesity is projected to affect over half of the global population by 2035.

Healthcare providers should prepare for increased obesity-related challenges.

Advances in omics technologies have enabled the identification of molecular subtypes and candidate biomarkers for obesity.

Utilizing omics technologies can enhance personalized approaches to obesity treatment.

No significant heterogeneity of treatment effects was found by age, race, ethnicity, baseline BMI, or baseline HbA1c.

GLP-1 receptor agonists may be effective regardless of age, race, ethnicity, BMI, or HbA1c levels.

People with MASH and clinically significant fibrosis are at risk of progressing to cirrhosis and hepatocellular carcinoma.

Monitoring and intervention are crucial for patients with MASH and fibrosis.

The net financial impact to Medicare was estimated to be savings of $715 million over 10 years.

Healthcare policymakers should recognize the potential cost savings associated with semaglutide for Medicare.

Availability of semaglutide in Medicare for all FDA-approved indications would yield net savings ranging from $1.04 billion to $412 million over 10 years.

Healthcare providers should advocate for the inclusion of semaglutide in Medicare to maximize economic and health benefits.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-third of the population.

Health practitioners should be aware of the high prevalence of MASLD in their patient populations.

The optimized nanocomplex of semaglutide with protamine and zinc exhibited a particle size of 196.0 nm and a zeta potential of -45.7 mV.

The nanocomplex's size and charge may influence its delivery and efficacy.